Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings AbbVie Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: AbbVie Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: AbbVie Inc.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 74.8 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Rating Financials

AbbVie Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

AbbVie Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

AbbVie Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

AbbVie Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

AbbVie Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
390B
AA
964B
A
515B
BBB
363B
AA
292B
A
272B
AAA
269B
A
265B
A
175B
A
151B
AAA
Average 365.61B
AA
Weighted average by Cap.
AA
See all sector ratings